Journal
ANTIVIRAL RESEARCH
Volume 169, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.antiviral.2019.104553
Keywords
HBV; Antiviral therapy; cccDNA; Chronic hepatitis B; Serum marker
Categories
Funding
- French National Research Agency as part of the second Investissements d'Avenir program [ANR-17-RHUS-0003]
- Agence Nationale pour la Recherche sur le SIDA et les hepatites virales (ANRS) [nN16003CR, nECTZ8323]
- Agence Nationale de la Recherche (ANR) [ANR-17-RHUS-0003] Funding Source: Agence Nationale de la Recherche (ANR)
Ask authors/readers for more resources
Chronic hepatitis B virus (HBV) infection remains a major health burden with over 250 million cases worldwide. This complex infection can lead to chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Complete recovery is seldom achieved due to the persistence in infected hepatocytes of covalently closed circular (ccc) DNA, which is not targeted by current antiviral therapies. Routine circulating biomarkers used for clinical monitoring of patients do not accurately reflect the cccDNA pool and transcriptional activity. New biomarkers, such as serum HB core-related Ag and circulating HBV RNAs, are under development. In this review, we discuss surrogate non-invasive biomarkers for evaluating intrahepatic cccDNA abundance and transcriptional activity. We also present their relevance for improving the classification of patients with regards to their natural history and for evaluating novel compounds to assess target engagement and to define new virological endpoints.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available